Trial Profile
A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5% in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Autoimmune disorders; Obsessive-compulsive disorders; Streptococcal infections
- Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
- Acronyms PANS
- 01 May 2020 Primary endpoint (Change in Yale Global Tic Severity Scale (YGTSS)) has been met, as per Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Primary endpoint (Change in Anxiety Disorders Interview Schedule for DSM-IV, Child, Parent Versions (ADIS)) has been met, as per Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Primary endpoint (Change in Childrens Yale-Brown Obsessive Compulsive Scale (CY-BOCS)) has been met, as per Results presented at the 72nd Annual Meeting of the American Academy of Neurology